Nasdaq:US$9.58 (+0.00) | HKEX:HK$16.36 (-0.66) | AIM:£1.61 (+0.02)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2017-09-28

CSCO 2017: Theliatinib Phase I Results

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial

Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong

Venue: Chinese Society of Clinical Oncology Annual Meeting
Session: Esophageal Cancer
Presenter: Jifang Gong
Date: Thursday, September 28, 2017